The sorangicins, novel and powerful inhibitors of eubacterial RNA polymerase isolated from myxobacteria.
- 1 January 1987
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 40 (1) , 7-13
- https://doi.org/10.7164/antibiotics.40.7
Abstract
A new antibiotic, sorangicin, was isolated from the culture supernatant of the myxobacterium, Sorangium (Polyangium) cellulosum strain So ce12. It is a macrocyclic lactone carbonic acid and is produced in two structural variants, sorangicins A and B. In addition small quantities of the respective glycosides, sorangiosids A and B, may be found. The antibiotic acts mainly against Gram-positive bacteria, including mycobacteria, with MIC values between 0.01 and 0.1 .mu.g/ml, but at higher concentrations (MIC 3 .apprx. 30 .mu.g/ml) Gram-negatives are also inhibited. Yeasts and molds are completely resistant. The new antibiotic is a specific inhibitor of eubacterial RNA polymerase which it blocks, however, only if added before RNA polymerization has started.This publication has 3 references indexed in Scilit:
- The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria.The Journal of Antibiotics, 1985
- The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales).The Journal of Antibiotics, 1983
- Mode of action of rifamycin on the RNA polymerase reactionBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1968